Compare HGLB & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HGLB | NYXH |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.6M | 152.8M |
| IPO Year | 2015 | 2021 |
| Metric | HGLB | NYXH |
|---|---|---|
| Price | $8.18 | $2.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | ★ 67.1K | 53.7K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $214.32 |
| Revenue Next Year | N/A | $124.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.23 | $2.76 |
| 52 Week High | $10.64 | $8.64 |
| Indicator | HGLB | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 49.34 |
| Support Level | $8.21 | $2.76 |
| Resistance Level | $9.06 | $3.32 |
| Average True Range (ATR) | 0.32 | 0.18 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 81.05 | 59.09 |
Highland Global Allocation Fund is a diversified, closed-end management investment company. The investment objective of the Fund is to seek long-term growth of capital and future income. The Fund seeks to achieve its investment objectives by investing in a portfolio of U.S. and foreign equity, debt, and money market securities. It may also invest in senior loans to domestic or foreign corporations, partnerships, and other entities that operate in a variety of industries and geographic regions.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.